Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster Associated Pain

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster Associated Pain

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valnivudine (Primary)
  • Indications Herpes zoster; Postherpetic neuralgia
  • Focus Registrational; Therapeutic Use
  • Sponsors Hepion Pharmaceuticals

Most Recent Events

  • 20 Dec 2017 Status changed from recruiting to discontinued.
  • 16 Jun 2016 According to ContraVir Pharmaceuticals media release, the company has anounced that it has amended the clinical trial protocol of this trial to more accurately represent the changing shingles population as seen in clinical practice and enroll the most clinically relevant patients into the study.
  • 15 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top